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Purpose: Encenicline (EVP-6124) is a selective α7
nicotinic acetylcholine receptor partial agonist being
developed for cognitive impairment in Alzheimer’s
disease and schizophrenia. We report on 2 single-
dose studies to assess the relative bioavailability,
pharmacokinetic proﬁle, tolerability, and cognitive
effects of encenicline in healthy volunteers.
Methods: A single ascending-dose study assessed
the safety, tolerability, pharmacokinetic, and pharma-
codynamic proﬁles of encenicline in healthy male
volunteers. Subjects received a single 1-, 3.5-, 7-,
20-, 60-, or 180-mg oral solution dose of encenicline
or placebo. A second single-dose, randomized,
open-label, 3-period, crossover study in healthy male
and female subjects compared the relative bioavail-
ability of a 1-mg oral capsule versus a 1-mg oral
solution dose of encenicline and evaluated the effects
of food and sex on encenicline pharmacokinetic
proﬁle.
Findings: In the ﬁrst study, encenicline was well
tolerated and dose-proportional increases in Cmax
(mean range 0.59100 ng/mL) and AUC01 (mean
range 45.68890 ng  h/mL) were observed over a 1-
to 180-mg dose range. Procognitive effects on the
Digit Symbol Substitution Test were maximal at theAccepted for publication September 16, 2014.
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February 201520-mg dose. In the second study, encenicline 1-mg
oral capsules and oral solution were bioequivalent and
there was no observed food effect on encenicline
pharmacokinetic proﬁle with the 90% conﬁdence
intervals of the treatment ratios for both comparisons
(ie, capsule to solution and fed to fasted) for Cmax and
AUC being within 80% to 125%. A 30% to 40%
higher encenicline exposure in female subjects than
respective values in male subjects was consistent with
a 33% higher weight of the male subjects. No
clinically relevant safety proﬁle or tolerability effects
of encenicline were observed.
Implications: Encenicline was well tolerated at
single doses up to 180 mg, and doses as low as 1
mg had dose- and time-dependent pharmacodynamic
effects on the central nervous system. Oral capsule
and solution were bioequivalent and were not affected
by food. Although a sex effect on pharmacokinetic
proﬁle was observed, it was attributable to weight
differences. Clinical Trial Registration at EudraCT:
2006-005623-42 and EudracT: 2008-000029-20.
(Clin Ther. 2015;37:311–324) & 2015 The Authors.
Published by Elsevier HS Journals, Inc.
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Clinical TherapeuticsINTRODUCTION
Studies have shown that nicotine can induce signiﬁcant
improvements in measures of attention and psycho-
motor processing in healthy volunteers1 and patients
with schizophrenia,2 attention-deﬁcit hyperactivity dis-
order,3 and Alzheimer’s disease.4 However, nicotine
interacts with multiple nicotine receptors, induces
receptor desensitization,5 is rapidly cleared, has a
signiﬁcant liability for addiction, and is associated
with toxicities such as induction of apoptosis, DNA
damage leading to oxidative stress, increases in
reactive oxygen species, and lipid peroxidation.6
Pharmacologic characterization of nicotine suggests
the α7 and α4β2 nicotinic cholinergic receptors
(nAcChR) as possible mediators of its procognitive
effects, although the afﬁnity of nicotine for the α7
receptor is substantially lower (approximately 2 log
units) than for the α4β2 receptor.7–9 Among these
nicotinic receptor targets, evidence suggests that acti-
vation of α7 nAcChR can be particularly relevant for
several aspects of cognition enhancement, including
higher cognitive functions,10 and such disease-speciﬁc
effects as the normalization of P50 auditory evoked
potential gating deﬁcits in schizophrenia11 and,
potentially, reduction of amyloid plaque accumu-
lation in Alzheimer’s dementia.12 The α7 nAcChR,
which is the target of encenicline, is composed of 5 α7
subunits13,14 forming a Ca2þ-permeable ion channel.
The α7 nAcChR is located in several brain areas
involved in cognition and memory, such as the
cerebral cortex and the hippocampus.15 It is
predominantly located presynaptically and inﬂuences
the release of neurotransmitters, such as γ-amino-
butyric acid, glutamate, acetylcholine, and dopa-
mine.16 Activation of the α7 nAcChR by an agonist
can be expected to increase cholinergic neurotrans-
mission.17 Depending on the brain region studied, α7
nAcChR agonists also will increase the release of
dopamine and glutamate.18,19 The α7 nAcChR sub-
unit has an additional advantage over the β2 nAcChR
subunit in that it does not appear to be involved in
activation of behavioral reward pathways and, there-
fore, may not be associated with the development of
addiction. It is hypothesized that α7 nAcChR agonists
can provide a cognitive beneﬁt without risk for
addiction.19,20 In the past few years, several selective
α7 nAcChR agonists16 have shown procognitive
effects in animals,21–23 healthy volunteers,24 and
patients with schizophrenia.25,26312Encenicline is an α7 nAcChR partial agonist that
demonstrates procognitive effects at low nanomolar
concentrations.27 This articles describes the safety,
tolerability, pharmacokinetic (PK), and pharma-
codynamic (PD) proﬁles of single oral doses of
encenicline in humans, as well as the results of a
single oral dose relative bioavailability study in fasted
and fed adult men and women.METHODS
For each study, the clinical study protocol, protocol
amendments, and informed consent forms were re-
viewed and approved by an Independent Ethics Com-
mittee (Stichting Beoordeling Ethiek Bio-Medisch
Onderzoek, Assen, the Netherlands). Both studies were
performed at PRA International, Zuidlaren, the Nether-
lands in accordance with the principles of the Declara-
tion of Helsinki and in compliance with the
International Conference on Harmonisation Guidelines
for Good Clinical Practice. All participants provided
written informed consent before participation.Single Ascending-Dose Study
Design
This was a randomized, double-blind, placebo-
controlled, single-center study. The study consisted
of 6 dose groups of 8 subjects each, 6 of whom were
randomly assigned to encenicline (1, 3.5, 7, 20, 60, or
180 mg encenicline HCl) and 2 to placebo. Enrollment
in any speciﬁc dose level occurred only after toler-
ability was established at the previous dose level.
Subjects were conﬁned to the facility the night before
dosing and remained there until at least 72 hours
post dose.Subject Selection
Healthy male subjects aged 18 to 45 years and
with a body mass index of 18 to 28 kg/m2 were
eligible if they had a medical history with no relevant
pathology. Subjects were excluded for an abnormal
EEG, use of concomitant medications other than
acetaminophen, use of tobacco products within 60
days before drug administration, positive drug screen,
positive hepatitis B surface antigen, antihepatitis C
virus, or antiHIV1/2 test, intake of >8 cups of
coffee or tea per day or intake of >24 units of
alcohol per week.Volume 37 Number 2
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Blood samples (4 mL) were obtained either via an
indwelling intravenous catheter or by direct venipunc-
ture into sodium heparin glass tubes at pre dose and at
0.5, 1, 2, 3, 4, 5, 6, 8, 24, 36, 48, and 72 hours post
dose for group 1 (1 mg). Additional ambulatory
blood-collection time points were added due to the
unexpected long plasma half-life (>50 hours) of
encenicline (96 and 120 hours in group 2 [3.5 mg],
and 168 and 240 hours post dose for subsequent
cohorts). Plasma encenicline concentrations were
measured using a validated liquid chromatography
method that employed tandem mass spectrometry
detection. In brief, 1500 μL acetonitrile was added
to 400 μL plasma (sodium heparin anticoagulant) and
50 μL internal standard (13C2,D2-encenicline) and
samples were vortexed for 60 seconds. After centrifu-
gation at 3500g for 5 minutes, 1 mL supernatant was
transferred to a glass tube and 100 μL 10% 1,2-
propanediol was added. The sample was reduced to
dryness under a stream of nitrogen at 401C. Recon-
stitution solvent (100 μL; 40% acetonitrile in water)
was added and the sample was transferred to injection
vials. A 40-μL aliquot was injected on the high-
performance liquid chromatography tandem mass
spectrometry system with detection based on monitor-
ing of mass transitions of 321.00 to 110.00 for
encenicline and 325.00 to 114.00 for internal stand-
ard using a Perkin Elmer API 4000 MS/MS detector
(MDS Sciex, Concord, Canada). The assay was
validated over a concentration range of 0.01 to 10
ng/mL, with an allowance for up to 400 ng/mL with
dilution. Adequate benchtop, autosampler, freeze and
thaw, whole blood, and frozen sample stability was
demonstrated. Encenicline PK parameters were deter-
mined using standard noncompartmental methods
using WinNonlin Professional Version 5.01. Cmax
and time of Cmax values were recorded as observed.
The terminal elimination rate constant (λz) for enceni-
cline was determined by regression of the terminal
log-linear portion of the plasma concentration-time
proﬁle. Terminal elimination half-life was calculated
as 0.693/λz. AUC from time zero to the time of the last
sample with quantiﬁable concentrations (AUC0last)
was determined using linear trapezoidal and logarith-
mic trapezoidal methods when plasma concentration
was increasing or decreasing, respectively. AUC from
time zero to inﬁnite time (AUC01) was determined
by summing AUC0last and Clast/λz, where Clast wasFebruary 2015the concentration of the last sample with quantiﬁable
concentrations.PD Assessments
PD assessments consisted of the Addiction Re-
search Center Inventory 49-item questionnaire
(ARCI49), Bond and Lader Visual Analogue Scale
(VAS), and the Digit Symbol Substitution Test
(DSST), which were performed pre dose and at 1,
2, 4, 8, and 24 hours post dose. The ARCI49 is a
self-rating scale to test subjective effects of drugs.28 It
is composed of 5 subscales: a Morphine Benzedrine
(MB) group scale to measure euphoria, A Lysergic
Acid Diethylamide group scale to estimate dysphoric
and psychotomimetic changes, a Pentobarbital Chlor-
promazine Alcohol (PCA) group scale to measure
sedation, and a Benzedrine group scale and an
Amphetamine Scale to assess stimulant effects.
Responses reported as “true” were scored as plus
or minus 1 on each relevant subscale. The Bond and
Lader VAS questionnaire assessed (1) self-rated alert-
ness, (2) self-rated calmness, and (3) self-rated con-
tentment.29 The DSST is a neuropsychological test
that explores attention, psychomotor speed, and
speed of processing30 and is sensitive for a variety
of neuropsychological impairments, including early
Alzheimer’s disease, with test performance correlating
to disease progression.31
Quantitative electroencephalogram (qEEG) was
performed at 1, 2, 3, 4, 6, 8, and 24 hours post
dose. For qEEG, silver/silver chloride disc electrodes
were attached to the scalp by means of quick-drying
collodion, according to the international standards
for EEG practice. The electrodes were placed over
T3, T4, F3, F4, O1, and O2. Linked earlobes were
used as common reference. The ground electrode
was located at the sternum. Electrodes were placed
by trained medical research assistants, according to
the international 1020 system. A 24-channel sta-
tionary recording system was used (Refa, TMS
International, Oldenzaal, the Netherlands). After
digital ﬁltering, data were digitized with a sampling
frequency of 256 Hz. During the data acquisition,
subjects were in the sitting position. The qEEG was
recorded during 5-minute resting conditions (subjects
were asked to relax with their eyes closed). Data
were analyzed off-line using BrainVision Analyzer
software.313
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Treatment-emergent adverse events, laboratory
evaluations (hematology, blood chemistry, and uri-
nalysis), physical examination, 12-lead ECG, cardio-
vascular telemetry monitoring, and Holter recordings
were monitored throughout the study. A 12-lead ECG
and vital signs were performed pre dose and at 1, 2, 3,
4, 5, 6, 8, 24, 48, 72 hours post dose for all dose
groups. ECG assessments were also conducted at 96
and 120 hours post dose for all dose groups other
than the 1-mg group. Cardiovascular telemetric mon-
itoring was in place from 10 minutes pre dose until 6
hours post dose, and a 3-lead Holter recording was
taken from 1.5 hours pre dose to 34.5 hours post
dose. Clinical laboratory studies were performed
at baseline and at 72 hours post dose in the 1-mg
dose group and at 72 and 120 hours post dose in the
other dosing groups. Determinations of B- and
T-lymphocyte counts were performed pre dose and
at 24 hours post dose.
Statistical Analysis
All PK data were summarized using descriptive
statistics. Dose proportionality was explored using
ANOVA on log-transformed and dose-normalized
Cmax and AUC parameters. For qEEG, a nonpara-
metric ANOVA was used to compare treatment
groups for change from baseline for AUC of the
frequency bands. Comparison of each active dose to
placebo was performed for the different frequency
bands, electrode positions, and time points. For the
ARCI49 questionnaire, Bond and Lader VAS, and
DSST, all data were summarized using descriptive
statistics, and change from baseline to end point was
summarized. To determine signiﬁcant differences be-
tween active dose and placebo changes from baseline
values, the ARCI49 and Bond and Lader VAS data
were analyzed using a repeated-measures ANOVA.
Least square means were used to estimate the overall
differences between active dose and placebo, as well as
differences at each time point. The total number of
correct responses on the DSST by treatment for each
time point, as well as the change from baseline, were
summarized using descriptive statistics. A within-
subject change using the modiﬁed Dunlap’s d statistic
was calculated according to the following formula:
change score ¼ (baseline  post baseline)/WSD
(group), where WSD is the within-subject SD of the
group from the 2 baseline conditions, baseline is the314last observed measurement before dosing, and post
baseline is the score on the scheduled post-baseline
measurements. Group mean effect sizes (ie, modiﬁed
Dunlap’s d change scores) were then compared be-
tween each active dose group and placebo using
independent t tests. All p values were 2-sided. Stat-
istical signiﬁcance was declared at the 0.05 level.
Capsule and Solution Relative Bioavailability and
Food and Sex Effect Study
Design
This was a single-dose, open-label, 3-period cross-
over study in one group of 12 male and female
subjects. The 3 treatments were administered in a
randomized sequence with at least 14 days’ wash out
between dosing occasions. Subjects received a single
dose of encenicline 1 mg as an oral capsule under fed
and fasting conditions, and as an oral solution under
fasting conditions.
Drug Administration
For the oral solution, encenicline 1 mg was ad-
ministered after an overnight fast in 4 mL cranberry
juice cocktail (vehicle), followed by an additional 180
mL of vehicle. For all treatment groups, no ﬂuids were
allowed from 2 hours before until 2 hours after drug
administration (except for 180 mL water used to
swallow the capsule or 180 mL cranberry juice taken
with the oral solution). On the day of dosing (day 1)
for treatment group A (oral capsule under fasting
conditions), treatment group B (oral capsule under fed
conditions), and treatment group C (solution under
fasting conditions), encenicline was administered be-
tween 10 AM and 11 AM after having received a light
supper the previous evening, followed by a 10-hour
overnight fast. For treatment groups A and C, fasting
was continued for 4 hours after drug administration
until lunch; for treatment group B, a standard break-
fast was consumed 30 minutes before dosing and was
completed at least 10 minutes before dosing. Lunch on
dosing days was given after the 4-hour PK sampling.
Study Assessments
Clinical laboratory, full physical examination (in-
cluding body weight), vital signs (blood pressure,
pulse rate and body temperature), 12-lead ECG,
medical history, drug and alcohol screen, hepatitis B
surface antigen, antihepatitis C virus, anti-HIV1/2,
and pregnancy test (females only) were obtained atVolume 37 Number 2
Table I. Baseline demographic characteristics.
Parameter/Statistics
Placebo
(n ¼ 12)
Encenicline Dose Group
1 mg
(n ¼ 6)
3.5 mg
(n ¼ 6)
7 mg
(n ¼ 6)
20 mg
(n ¼ 6)
60 mg
(n ¼ 6)
180 mg
(n ¼ 6)
Age, y
Mean (SD) 25 (6) 23 (4) 31 (10) 27 (8) 22 (2) 21 (2) 26 (7)
Range 1941 1831 2044 2042 2026 1926 2041
Height, cm
Mean (SD) 181 (5) 187 (6) 180 (5) 181 (8) 186 (3) 184 (5) 179 (6)
Range 171188 179195 174185 168193 182189 177191 170189
Weight, kg
Mean (SD) 78.9 (10.3) 81.7 (6.8) 77.8 (7.4) 79.6 (7.4) 82.5 (8.6) 76.8 (11.7) 76.7 (11.4)
Range 58.893.9 70.591.2 66.288.5 67.789.5 67.992.2 64.291.2 63.989.6
BMI, kg/m2
Mean (SD) 24.0 (2.4) 23.5 (1.7) 23.9 (2.0) 24.3 (2.4) 23.9 (2.0) 22.6 (2.9) 24.0 (3.2)
Range 18.626.9 21.725.6 20.925.9 20.027.0 20.325.8 19.027.2 20.328.0
BMI ¼ body mass index.
A.J. Barbier et al.baseline. Drug and alcohol screen, vital signs (blood
pressure, pulse rate, and body temperature), body
weight, clinical laboratory, ECG, pregnancy test
(females only), concomitant medication, and adverse
events were obtained routinely during the study.
Blood samples for PK proﬁle of encenicline were
obtained pre dose and at 0.5, 1, 2, 3, 4, 6, 8, 12,
24, 36, 48, 72, 120, 168, and 240 hours post dose.
Plasma concentrations of encenicline were determined
using a validated liquid chromatography tandem mass
spectrometry method, as described. Encenicline PK
parameters were determined using noncompartmental
methods with WinNonlin Professional Version 5.01.
Statistical Analysis
The bioavailability of encenicline from the oral
capsule formulation relative to the oral solution formu-
lation in the fasted state was assessed using an ANOVA
on log-transformed encenicline Cmax, AUC0t, and
AUC01 values. Point estimates and 90% conﬁdence
intervals (CIs) for the treatment differences on the log
scale were exponentiated to obtain estimates and 90%
CIs for the geometric mean ratios on the original scale.
In addition, the effect of food and sex on the relative
bioavailability of encenicline after single oral adminis-
tration as a capsule was assessed based on determinationFebruary 2015of 90% CIs for the ratio of the means, using log-
transformed data for Cmax, AUC0.t, and AUC01.
RESULTS
Single Ascending-Dose Study
Demographics
Forty-eight subjects were enrolled, received study
medication, and completed PD assessments. Demo-
graphic characteristics generally were comparable
between groups at baseline (Table I).
PK of Encenicline
Across the study sample bioanalytical runs, the
accuracy (% bias) of encenicline quality-control samples
(0.03 ng/mL to 8.00 ng/mL) ranged from 2.2% to 5.3%
and assay precision (%CV) ranged from 3.5% to
21.3%. After oral administration of encenicline at single
doses ranging from 1 mg to 180 mg, median Tmax values
ranged from 5.0 to 8.0 hours (Table II and Figure 1). An
ANOVA analysis of the extent of systemic exposure, as
measured by either Cmax or AUC01, revealed an
increase in a dose-proportional manner over the entire
dosing range (1 to 180 mg). Mean terminal elimination
half-life values ranged from 52.6 to 63.0 hours and were
independent of dose. There was no apparent dose
relationship of mean oral clearance values (20.2 to315
Table II. Arithmetic mean (%CV) pharmacokinetic parameters for encenicline after administration as an oral
solution.
Parameter
Encenicline HCl Dose
1 mg 3.5 mg 7 mg 20 mg 60 mg 180 mg
Tmax, h, median (range) 5.0 (3.06.0) 8.0 (5.08.0) 5.0 (4.08.0) 5.0 (5.08.0) 6.0 (2.08.0) 5.0 (5.08.0)
Cmax, ng/mL, mean (%CV) 0.588 (23) 2.06 (20) 4.66 (16) 10.4 (10) 35.6 (11) 100 (17)
AUC0last, ng  h/mL, mean
(%CV)
27.4 (24) 116 (30) 306 (9) 780 (18) 2400 (18) 8200 (23)
AUC01, ng  h/mL, mean
(%CV)
45.6 (33) 165 (34) 358 (21) 852 (22) 2800 (23) 8890 (24)
λz, 1/h, mean (%CV) 0.0145 (30) 0.0118 (20) 0.0122 (24) 0.0127 (23) 0.0113 (17) 0.0117 (17)
T½, h, mean (%CV) 52.6 (37) 60.8 (22) 60.3 (30) 57.0 (21) 63.0 (15) 60.6 (17)
CL/F, L/h, mean (%CV) 23.9 (31) 23.1 (30) 20.2 (19) 24.6 (25) 22.4 (22) 21.3 (24)
Vz/F, L, mean (%CV) 1740 (37) 1970 (28) 1680 (10) 1950 (13) 1990 (14) 1810 (16)
CL/F ¼ oral clearance; λz ¼ terminal elimination rate constant; Vz/F ¼ volume of distribution of the terminal elimination phase.
Clinical Therapeutics24.6 L/h) or apparent volume of distribution of the
terminal elimination phase (Vz/F) values (1680 to 1990
L). The degree of variability in PK parameters was low,
with most %CV values o25%.
Quantitative EEG
Overall, results from the qEEG analysis suggested
that encenicline might have some PD effects. How-
ever, a clear and consistent pattern over time or dose
relationship was not established. Encenicline had no
signiﬁcant effect on absolute power levels. However,
the relative contributions of individual frequency
bands in relation to the entire EEG frequency range
did show changes with dose and time of measurement.
Inspection of the relative power in the EEG signal
showed that the contribution of individual frequency
bands in relation to the entire EEG frequency range
did show changes with dose and time of measurement
(dose  band: p r 0.001; dose  time  band: p r
0.001). The contribution of α frequencies (812.5 Hz)
increased compared with power observed in the
placebo group, especially for the lower doses of
encenicline (1, 3.5, and 7 mg). These effects remained
until 8 hours after administration of the active dose.
Effects on relative α power in the 1-mg dose group
disappeared after 8 hours; however, for the 3.5- and
7-mg doses, the increase of α frequencies in the EEG
signal remained visible until 24 hours after adminis-
tration. In the β (1332 Hz) and δ (0.53.5 Hz)
frequency bands, relative power levels decreased in316comparison with baseline levels (p r 0.001). In the
3-hour period after administration of encenicline, the
observed decrease in relative δ power was most pro-
nounced with the 3.5-mg dose. Thereafter, the decrease
in relative power in the δ band was most apparent with
the 60-mg dose. The observed decrease in relative β
power was most prominent for the 7-mg and 20-mg
doses early after administration of encenicline, and 3
hours after dose administration, effects were observed
with the 180-mg dose as well. Relative τ power was not
affected by either dose or time of measurement. The
relative increase in α power in combination with a
decrease of power in the δ frequency band resulted in
effects on the α slow-wave index. The change in α slow-
wave index was observed most clearly in occipital leads,
in the O1 and O2 electrodes. This effect was most
pronounced for the 7-, 20-, and 60-mg dose on the left
side (O1) and for the 3.5-mg and 7-mg dose on the right
side of the brain (dose  channel: p r 0.001). On the
other electrode sites (F3, F4, T3, and T4), the α slow
wave index did not show signiﬁcant changes.
DSST Test
The effects (modiﬁed Dunlap’s d change score) of
procedural learning and repeated practice led to some
improvements in performance from baseline during the
course of 24 hours in all dose groups (Figure 2).
However, there was a clear drug effect above these
learning and practice effects. Across all dose groups
and time points, the modiﬁed Dunlap’s d effect sizesVolume 37 Number 2
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Figure 1. Arithmetic mean (SD) plasma concentration versus time profiles for encenicline at doses of 1 to 180
mg as an oral solution. (A) Linear and (B) semi-log plot.
A.J. Barbier et al.ranged from 0.1 to 5.7. The improvement in DSST
was generally dose dependent, initially increasing with
increasing dose, but with an apparent U-shaped dose–
response curve and with the effect in the 3.5-mg group
being somewhat muted (Figure 2). The maximal effect
(d ¼ 3.35.7) was observed at the 20-mg dose, with a
diminution in peak improvement at the 60-mg and
180-mg doses, Statistically signiﬁcant differences were
observed at the lowest (1 mg) dose group, for which the
modiﬁed Dunlap’s d effect size was 1.7 at 1 hour after
dosing, which was more than twice the magnitude of
the placebo effect (p ¼ 0.016). Signiﬁcant differences
versus placebo (p r 0.050) were also observed for the
1-mg dose group at 24 hours post dose, the 7-mg dose
group at 8 hours and 24 hours post dose, the 20-mgFebruary 2015dose group at 4 hours post dose, and the 60-mg dose
group at 8 hours post dose.
ARCI49
No statistically signiﬁcant dose effects were ob-
served for the MB, Lysergic Acid Diethylamide,
PCA, Amphetamine, or Benzedrine group scales.
Statistically signiﬁcant differences were observed on
comparison of placebo-corrected change from baseline
values based on dose or by dose and time point for the
following (p r 0.050): dose, increase in MB group
scale at 60 mg and decrease in PCA group scale at 1
mg and 180 mg; dose by time point, increase in
Amphetamine scale at 180 mg at 24 hours, increases
in MB group scale at 60 mg at 8 hours and 180 mg at317
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Figure 2. Mean (SE) modified Dunlap’s d change scores for Digit Symbol Substitution Test by encenicline
dose level and time. *p r 0.050 versus placebo.
Clinical Therapeutics24 hours, decreases in PCA group at 1 mg at 2 hours
and 180 mg at 2, 4, and 24 hours. Overall, based
on the lack of a dose or time relationship of the
statistically signiﬁcant increases in subscale values
the ARCI data suggest encenicline does not have
negative effects on endpoints potentially relevant for
misuse/abuse.Bond and Lader VAS
Based on repeated-measures ANOVA, no statisti-
cally signiﬁcant dose effects were observed for the
alertness, contentedness, or calmness subscales of
the Bond and Lader VAS. On comparison of
placebo-corrected change from baseline values, a
statistically signiﬁcant increase in alertness was ob-
served at the 1-, 7-, 60-, and 180-mg encenicline dose
levels. Based on a dose by time point analysis of
placebo-corrected change from baseline values, stat-
istically signiﬁcant increases in alertness were ob-
served at 1 and 2 hours post dose at 1 mg, at 24
hours post dose at 60 mg, and at all post-dose time
points at 180 mg. Statistically signiﬁcant decreases in
calmness were observed at 2 and 8 hours post dose at
1 mg, and in contentedness at 24 hours post dose at 1
mg. Overall, the Bond and Lader VAS suggest a
potential increase in self-rated alertness at the 180-
mg encenicline dose level. The data for self-rated
calmness and contentedness showed no clear effect
of encenicline during the study.318Safety and Tolerability
Thirty-ﬁve adverse events (AEs) were reported by 22
of the 48 subjects. Nine AEs were reported before study
drug administration, resulting in a total of 26 treat-
ment-emergent AEs (TEAEs) reported by 20 subjects
(Table III). The most frequently reported TEAEs were
headache (6 events reported by 5 subjects) and rhinitis
(3 events reported by 3 subjects). Of the 26 TEAEs,
4 reported by 4 subjects were considered possibly related
to treatment: dizziness (2 events; placebo) nausea (1 event;
600 mg dose), and eye irritation (1 event; 20-mg
dose). No relationship between TEAEs and increasing
doses was observed. No serious AEs, deaths, or
discontinuations due to AEs were reported.Capsule and Solution Relative Bioavailability and
Food and Sex Effect Study
Demographics
Twelve subjects were enrolled, 7 female and 5 male,
and 11 completed the study. One subject was withdrawn
because of inﬂuenza-like illness. Mean (SD) age was 51
(16) years, and mean (SD) BMI was 25.0 (3.0) kg/m2.
On average, male subjects were older and had higher
mean body weight and BMI. Eleven subjects were white
and one female deﬁned her race as white and Asian.PK Evaluation
Across the study sample bioanalytical runs, the
accuracy (% bias) of encenicline quality-control samplesVolume 37 Number 2
Table III. Treatment emergent adverse events occurring in Z2 subjects overall.
Adverse Event
Subjects, n (%)
Encenicline Dose Group
Placebo
(n ¼ 12)
1 mg
(n ¼ 6)
3.5 mg
(n ¼ 6)
7 mg
(n ¼ 6)
20 mg
(n ¼ 6)
60 mg
(n ¼ 6)
180 mg
(n ¼ 6)
Any AE 6 (50) 4 (67) 1 (17) 2 (33) 3 (50) 4 (67) 0
Rhinitis 1 (8) 2 (33) 0 0 0 0 0
Dizziness 2 (17) 0 0 0 0 0 0
Headache 1 (8) 1 (17) 0 0 2 (33) 1 (17) 0
Pharyngolaryngeal pain 1 (8) 0 0 0 0 1 (17) 0
AE ¼ adverse event.
A.J. Barbier et al.(0.038.00 ng/mL) ranged from 2.1% to 3.0% and
assay precision (%CV) ranged from 1.7% to 5.8%.
Mean plasma encenicline concentration-time proﬁles
were similar after the oral solution and capsule for-
mulations and after administration of a capsule under
fed or fasted conditions. Encenicline Cmax was reached
at median times of 6 hours for the oral capsule and 7
hours for the oral solution (Figure 3). Thereafter, a
gradual decline in mean plasma concentrations was
observed with quantiﬁable concentrations observed up
to 240 hours post dose. Encenicline PK parameters were
similar after administration as a capsule relative to an
oral solution, with point estimates and 90% CIs of the
ratio of log-normalized parameters being 104% (98%
111%) for Cmax, 109% (104%115%) for AUC0last
and 109% (104%115%) for AUC01. Therefore,
encenicline administered as a capsule formulation was
bioequivalent to administration as an oral solution.
After encenicline 1-mg capsules under fed and fasting
conditions, median Tmax was similar (6 hours) and mean
t½ was 67.1 versus 67.4 hours, respectively. Mean Cmax
(0.762 vs 0.717 ng/mL), AUC0t (65.4 vs 62.3 ng  h/
mL), and AUC01 (71.8 vs 68.6 ng  h/mL) were similar
for oral capsules under fasting and fed conditions,
respectively. The 90% CIs of the treatment ratios (fed
over fasted) for Cmax and AUC parameters were within
80% to 125%, indicating that administration with food
did not affect encenicline PK proﬁle. After encenicline 1-
mg oral capsules or solution, mean plasma concentra-
tions and exposure parameters were higher in female
versus male subjects (Figure 4) with the ratios and
90% CIs of log-normalized parameters being 142%February 2015(117%172%) for Cmax, 130% (103%165%) for
AUC0last, and 128% (98%168%) for AUC01; the
sex difference in Cmax was statistically signiﬁcant (p r
0.050) (Figure 5). The approximate 30% to 40% higher
Cmax and AUC parameters observed in female subjects
was consistent with the, on average, 33% greater body
weight of the male subjects (84.0 kg) enrolled in the
study compared with the female subjects (66.4 kg).
Tolerability
Twenty-three TEAEs were reported by 10 of the 12
subjects (83%). Four subjects each reported one or
more TEAEs of moderate severity, only one of which
(nausea) was considered possibly related to study
medication. Five TEAEs were considered to be possi-
bly drug related: headache (3 events, fasted capsule
[n ¼ 1] or solution fasted [n ¼ 2] subjects); dizziness
(1 event, in fasted capsule subject), and nausea
(1 event, solution fasted). No deaths occurred during
the study, and no serious AEs or severe TEAEs
were reported. No clinically relevant changes in vital
signs, 12-lead ECG, telemetric monitoring, Holter
monitoring, laboratory parameters (including immu-
nology assessment), and physical examination were
observed.
DISCUSSION
This article reports the ﬁrst clinical experience with
encenicline, a selective α7 nAcChR partial agonist. The
results indicate that, after oral administration in
healthy male volunteers, single doses of encenicline
from 1 to 180 mg exhibited linear kinetics. Encenicline319
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Figure 3. Arithmetic mean (SD) plasma concentration versus time profiles for encenicline after administration
of 1-mg oral capsule in fasted and fed states or 1-mg oral solution in fasted state.
Clinical Therapeuticswas quantiﬁable in plasma at all doses administered.
Absorption was somewhat prolonged, with a Tmax in
the 5- to 7-hour range. Encenicline had a long plasma
half-life (estimated 5462 hours) and a high volume
of distribution of the terminal phase (16801990 L).
It is anticipated that once-daily dosing with enceni-
cline will be appropriate for evaluation of the safety
and efﬁcacy proﬁles for extended periods. The bio-
availability of encenicline was similar for oral capsule
and oral solution and was not affected by food, but
higher Cmax and AUC values were observed in female1.2 Solution males (n =
Capsule males (n =
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of 1-mg oral capsule or solution in fasted stat
320versus male subjects, which likely was associated with
the higher body weight of male subjects.
Encenicline was very well tolerated after single oral
doses of 1 to 180 mg. Most adverse events were of mild
or moderate severity, and no serious adverse events
occurred. All the adverse events considered related to
treatment were mild, and no evidence of a dose-
dependency for speciﬁc adverse events was noted.
Encenicline had no apparent effect on absolute
power levels of the EEG, but the relative contributions
of individual frequency bands in relation to the entire 5)
 5) Capsule females (n = 6)
Solution females (n = 7)
20 144 168 192 216 240
nistration (hours)
rsus time profiles for encenicline after administration
e in males and females.
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Figure 5. Point estimates and 90% confidence intervals (%) for encenicline AUC and Cmax parameters for the
comparisons of encenicline capsules and solution, the effect of food on encenicline capsules, and
the sex effect after administration of encenicline oral capsules.
A.J. Barbier et al.EEG frequency range did show changes with dose and
time of measurement. In general, the contribution of
frequencies in the α band increased, especially at the
lower doses, while the contribution of the β and δ band
attenuated. This latter effect was seen mainly at the
higher doses and was delayed in time compared with
the effects on the α band. One of the challenges of early
drug development targeting central nervous system
indications is the difﬁculty of attaining adequate central
nervous system penetration. Various techniques, such
as positron emission tomography scans, determinations
of compound level in the cerebrospinal ﬂuid, and
functional magnetic resonance imaging have been used
in attempts to develop an understanding of the PK to
PD proﬁle relationship of potential drugs. In the
absence of a high-afﬁnity, selective positron emission
tomography ligand for neuroimaging studies, we chose
qEEG and the DSST test as noninvasive methods
indicative of a PD effect of encenicline in humans and
these measures did show a response to drug.
No consensus exists about the link between speciﬁc
brain-wave frequency ranges and cognitive activity or
ability. Both τ and α activity have been implicated in
memory function.32 Some groups have found thatFebruary 2015cognition-enhancing compounds, including acetylcholi-
nesterase inhibitors, increase τ activity.33 In contrast,
cholinesterase inhibitors generally decrease τ activity in
patients with Alzheimer’s disease.34,35 This, however,
may reﬂect more of a muscarinic than a nicotinic effect.
At the present time, there is limited knowledge about
the effect of nicotinic agonists on EEG, and more
speciﬁcally of α7 nAcChR agonists. The nicotinic
agonist metanicotine decreased δ and α2 power, while
the selective α7 nAcChR antagonist methyllycaconitine
increased power in these ranges.36 The α7 nAcChR
agonist PNU-282987 did not inﬂuence rat hippocampal
τ rhythm by itself, but augmented τ activity induced by
electrical stimulation of the brain reticular formation37
and administration of amphetamine.38 To our
knowledge, this is the ﬁrst report of the effect of a
selective α7 nAcChR agonist on the EEG of the human
brain. In healthy male volunteers, TC-1734 (AZD3480,
ispronicline), a selective agonist of the α4β2 neuronal
AcChR, acceleration of the α centroid and of the α peak
was observed, mostly around 1 to 2 hours.39
Electroencephalography has been found to be
useful in the diagnosis of Alzheimer’s disease.40
Patients suffering from Alzheimer’s disease show an321
Clinical Therapeuticsincrease of slow EEG activity (δ and τ) at the expense
of α power, which might be expected to result in an
effect on the α slow-wave index.41,42 In the present
study, the α slow-wave index was found to be sensitive
to different doses of encenicline (7, 20, and 60 mg),
which might be regarded as preliminary support for a
PD effect of encenicline on the central nervous system.
The DSST was included as a measure of cognitive
performance. Changes in the DSST with encenicline
indicated improvement in a dose-dependent manner and
with no adverse effect on cognitive performance in this
normal population at all doses tested. The mean
modiﬁed Dunlap’s d scores (DSST) for the groups
treated with encenicline appear to increase over time
for nearly all doses. At 8 hours, all encenicline treatment
groups’ mean scores were higher than placebo and at 24
hours, all encenicline treatment groups’ mean scores,
with the exception of the 3.5-mg dose group, were
higher than placebo. This might indicate a positive PD
effect occurring after Tmax at 5 to 8 hours. The maximal
effects on DSST were observed at a single dose of 20 mg,
but signiﬁcant effects were observed even at the lowest
(1 mg) dose and continued during a 24-hour period. At
doses higher than 20 mg, there was an apparent
diminution of the positive DSST effects, suggesting that
a U-shaped dose response curve might exist, which is
compatible with receptor desensitization. The maximal
(optimal) procognitive effect of encenicline on the DSST
at a dose of 20 mg produces a mean exposure that
extrapolates to a steady-state (chronic) dosage per
exposure of 2 to 4 mg/d. There were no within-group
plasma concentration differences that would explain the
lower effect observed in the 3.5-mg dose group. Based
on an accumulation ratio of approximately 5, repeat
daily administration of 4 mg would be expected to result
in plasma concentrations similar to those observed after
a single 20-mg dose. Additional studies are needed to
evaluate whether long-term therapy in the 2 to 4 mg/d
dosage range might be optimal.
CONCLUSIONS
Encenicline appeared to be well tolerated at single doses
up to 180 mg in the population studied. Quantitative
EEG and the DSST indicated that, even at low doses,
encenicline appeared to have PD effects on the central
nervous system. Importantly, to our knowledge, this is
the ﬁrst report of the effect of a selective α7 nAcChR
agonist on the EEG of the human brain. No effect of
food on the PK proﬁle of encenicline was observed and,322although a sex PK effect was observed, it appears to be
related to weight differences in the subjects and is not
believed to represent sex-speciﬁc differences in the dis-
position and metabolism of encenicline. Additional clin-
ical studies are needed to investigate the anticipated
procognitive effects and the safety and tolerability proﬁles
of encenicline after multiple dosing. Dosages in the 2 to 4
mg/d range might provide optimal procognitive effects,
but this will require additional studies to conﬁrm.
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